Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 1/20 | 0.43 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 8/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | PTGES | O14684 | 1/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 2/20 | 0.37 |
| ▸ | CCR1 | P32246 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6315362 | 0.87 | RXFP1 (0.46) | ADORA2AADORA1ROCK2NPC1MEN1 | |
| SCHEMBL6321408 | 0.86 | EPHX2 (0.44) | EPHX2RORCKMT2A | |
| SCHEMBL6317961 | 0.85 | ALDH1A1 (0.45) | NPC1MEN1KMT2A | |
| SCHEMBL6316239 | 0.85 | HPGD (0.44) | ADORA2AADORA1NPC1MEN1HPGD | |
| SCHEMBL6319043 | 0.85 | NPC1 (0.46) | ADORA2AADORA1NPC1MEN1CYP1A2 | |
| SCHEMBL6315709 | 0.85 | CHRNB2 (0.43) | ADORA2AADORA1NPC1MEN1KMT2A | |
| SCHEMBL6317666 | 0.85 | TACR1 (0.46) | — | |
| SCHEMBL6324110 | 0.84 | MAPT (0.50) | NPC1CYP1A2CYP2D6HPGDCYP2C19 | |
| SCHEMBL6317698 | 0.83 | MLYCD (0.44) | CNR2ADORA1CCR1NPC1MEN1 | |
| SCHEMBL6316721 | 0.83 | NPC1 (0.55) | PSMB5ADORA2AADORA1NPC1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050059657-A1 | Aminoisoxazole derivatives active as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2005-03-17 | — | — | US | claimed |
| CN-1549714-A | Aminoisoxazole derivatives active as kinase inhibitors | — | 2004-11-24 | — | — | CN | claimed |
| EP-1435948-A1 | AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | Pharmacia Italia S.p.A. (IT) | 2004-07-14 | — | — | EP | claimed |
| WO-2003013517-A1 | AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | PHARMACIA ITALIA S.P.A. (IT) | 2003-02-20 | — | — | WO | claimed |
| US-20050059657-A1 | Aminoisoxazole derivatives active as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2005-03-17 | — | — | US | disclosed |
| EP-1435948-A1 | AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | Pharmacia Italia S.p.A. (IT) | 2004-07-14 | — | — | EP | disclosed |
| WO-2003013517-A1 | AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | PHARMACIA ITALIA S.P.A. (IT) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059657-A1 | Aminoisoxazole derivatives active as kinase inhibitors | MAP3K9, MAP3K19, MAP4K2 | NTRK1 1849/4885PSMB5 948/4885EPHX2 4156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.